
    
      A 12 month, prospective, randomized, single center, open-label study to evaluate the safety
      and efficacy of Rabbit anti-thymocyte globulin versus IL2 receptor antagonists in combination
      with tacrolimus, corticosteroids and mycophenolate mofetil in a predominantly high risk
      kidney transplant population.
    
  